Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 232Lymphoma 46Lymphoma, Mantle-Cell 44Neoplasms, Plasma Cell 40Recurrence 30Lymphoma, Non-Hodgkin 29Lymphoma, Follicular 26Leukemia, Myeloid, Acute 25Lymphoma, Large B-Cell, Diffuse 22Waldenstrom Macroglobulinemia 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Lymphoma, B-Cell, Marginal Zone 19Leukemia, Lymphocytic, Chronic, B-Cell 19Carcinoma, Non-Small-Cell Lung 18Leukemia 15Hodgkin Disease 13Neoplasms 12Immunoglobulin Light-chain Amyloidosis 12Hematologic Neoplasms 11Unspecified Adult Solid Tumor, Protocol Specific 9Myelodysplastic Syndromes 9Lymphoma, B-Cell 9Burkitt Lymphoma 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Large-Cell, Anaplastic 8Head and Neck Neoplasms 8Congenital Abnormalities 8Breast Neoplasms 8Sarcoma 7Lymphoma, Extranodal NK-T-Cell 7

Interventions

Fluorouracil 2Docetaxel 2thymoglobulin 1temsirolimus 1sargramostim 1pirarubicin 1pembrolizumab 1pazopanib 1fludarabine phosphate 1fludarabine 1cc-486 1X-Rays 1Whole-Body Irradiation 1Trastuzumab 1Tacrolimus 1Surveys and Questionnaires 1Rituximab 1Radiotherapy 1Proctectomy 1Pemetrexed 1Oxaliplatin 1Mycophenolic Acid 1Monatide (IMS 3015) 1Metformin 1Melphalan 1Leucovorin 1Granulocyte-Macrophage Colony-Stimulating Factor 1Epirubicin 1Drug Therapy 1Diphenhydramine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pathologic Complete Response × Bortezomib × Clear all
NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Millennium Pharmaceuticals, Inc.

Phase 2 Completed
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡